3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
1
Interventions
Dexamethasone
140
Lenalidomide
60
Bortezomib
56
Calcium Dobesilate
48
Melphalan
44
carfilzomib
40
pomalidomide
39
Cyclophosphamide
38
daratumumab
27
belantamab mafodotin
22
ixazomib
19
Peripheral Blood Stem Cell Transplantation
18
fludarabine phosphate
16
fludarabine
16
dexamethasone acetate
14
Bendamustine Hydrochloride
14
Whole-Body Irradiation
13
Filgrastim
13
dexamethasone 21-phosphate
12
Tacrolimus
12
venetoclax
11
auricularum
11
Prednisone
11
selinexor
10
liposomal doxorubicin
10
iberdomide
10
Mycophenolic Acid
10
isatuximab
9
Cyclosporine
9
pembrolizumab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
melflufen
×
Plasma cell
×
Clear all
NCT03481556
2022-12-19
ANCHOR
Oncopeptides AB
Phase 1/2
Terminated
56 enrolled
22 charts